Patents by Inventor Scott Lauder

Scott Lauder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR TREATING INFLAMMATORY OCULAR DISEASES WITH COMPLEMENT FACTOR H
    Publication number: 20240024416
    Abstract: The present disclosure relates to dosage regimens of complement factor H (CFH) protein for treating patients having inflammatory ocular diseases or conditions (e.g., age-related macular degeneration or early-onset macular dystrophies). The present disclosure also provides methods of treating patients having inflammatory ocular diseases, disorders, or conditions (e.g., age-related macular degeneration) using complement factor H (CFH) based on the levels of certain protein biomarkers, such as complement components and inflammation markers, in ocular samples of the patients.
    Type: Application
    Filed: October 29, 2021
    Publication date: January 25, 2024
    Inventors: Suresh Katti, Scott Lauder, Robyn Biggs, Walter Strapps, Lenore von Krusenstiern
  • Factor H potentiating antibodies and uses thereof
    Patent number: 11820814
    Abstract: Provided herein are novel isolated, synthetic or recombinant antibodies and fragments thereof specific for factor H, or nucleic acids or vectors encoding such antibodies and fragments. Further provided herein is the use of such antibodies, fragments, nucleic acids or vectors for inhibiting complement activation and treatment of disorders associated with complement activation.
    Type: Grant
    Filed: July 17, 2020
    Date of Patent: November 21, 2023
    Assignees: GEMINI THERAPEUTICS SUB, INC., STICHTING SANQUIN BLOEDVOORZIENING
    Inventors: Scott Lauder, Tom Purcell, Sridhar Govindarajan, Taco Willem Kuijpers, Diana Wouters, Maria Clara Brouwer, Richard Benjamin Pouw, Taede Rispens, Ilse Jongerius, Gillian Dekkers
  • METHODS FOR TREATING PATIENTS HAVING CFH MUTATIONS WITH RECOMBINANT CFH PROTEINS
    Publication number: 20220395557
    Abstract: The present disclosure provides methods for treating, preventing, or inhibiting diseases in patients having one or more mutations in complement factor H (CFH), complement component 3 (C3), and complement factor B (CFB). Also provided are combination therapies comprising a CFH protein and a VEGF antagonist for treating neovascularization-associated ocular diseases.
    Type: Application
    Filed: October 23, 2020
    Publication date: December 15, 2022
    Inventors: James McLaughlin, Lisa Huang, Scott Lauder, Suresh Katti
  • FACTOR H POTENTIATING ANTIBODIES AND USES THEREOF
    Publication number: 20220372120
    Abstract: Provided herein are novel isolated, synthetic or recombinant antibodies and fragments thereof specific for factor H, or nucleic acids or vectors encoding such antibodies and fragments. Further provided herein is the use of such antibodies, fragments, nucleic acids or vectors for inhibiting complement activation and treatment of disorders associated with complement activation.
    Type: Application
    Filed: July 17, 2020
    Publication date: November 24, 2022
    Inventors: Scott LAUDER, Tom PURCELL, Sridhar GOVINDARAJAN, Taco Willem KUIJPERS, Diana WOUTERS, Maria Clara BROUWER, Richard Benjamin POUW, Taede RISPENS, Ilse JONGERIUS, Gillian DEKKERS
  • METHODS FOR TREATING PATIENTS HAVING CFI MUTATIONS WITH RECOMBINANT CFI PROTEINS
    Publication number: 20220347265
    Abstract: The present disclosure provides methods for treating, preventing, or inhibiting diseases in patients having one or more CFI mutations.
    Type: Application
    Filed: October 23, 2020
    Publication date: November 3, 2022
    Inventors: James McLaughlin, Lisa Huang, Scott Lauder, Suresh Katti, Adam Tellier
  • IL-7 fusion proteins
    Patent number: 8338575
    Abstract: The invention is directed to a fusion protein which includes a first portion including an immunoglobulin (Ig) chain and a second portion including interleukin-7 (IL-7).
    Type: Grant
    Filed: May 18, 2011
    Date of Patent: December 25, 2012
    Assignee: Merck Patent GmbH
    Inventors: Scott Lauder, Stephen D. Gillies
  • IL-7 FUSION PROTEINS
    Publication number: 20110243887
    Abstract: The invention is directed to a fusion protein which includes a first portion including an immunoglobulin (Ig) chain and a second portion including interleukin-7 (IL-7).
    Type: Application
    Filed: May 18, 2011
    Publication date: October 6, 2011
    Applicant: Merck Patent GmbH
    Inventors: Scott Lauder, Stephen D. Gillies
  • IL-7 fusion proteins
    Patent number: 7960514
    Abstract: The invention is directed to a fusion protein which includes a first portion including an immunoglobulin (Ig) chain and a second portion including interleukin-7 (IL-7).
    Type: Grant
    Filed: December 4, 2007
    Date of Patent: June 14, 2011
    Assignee: Merck Patent GmbH
    Inventors: Scott Lauder, Stephen D. Gillies
  • FC-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
    Publication number: 20090092607
    Abstract: The present invention provides Fc-erythropoietin (“Fc-EPO”) fusion proteins with improved pharmacokinetics. Nucleic acids, cells, and methods relating to the production and practice of the invention are also provided.
    Type: Application
    Filed: September 26, 2008
    Publication date: April 9, 2009
    Applicant: Merck Patent GmbH
    Inventors: Stephen D. Gillies, Scott Lauder
  • IL-7 Fusion Proteins
    Publication number: 20090010875
    Abstract: The invention is directed to a fusion protein which includes a first portion including an immunoglobulin (Ig) chain and a second portion including interleukin-7 (IL-7).
    Type: Application
    Filed: December 4, 2007
    Publication date: January 8, 2009
    Inventors: Scott Lauder, Stephen D. Gillies
  • Fc-erythropoietin fusion protein with improved pharmacokinetics
    Patent number: 7465447
    Abstract: The present invention provides Fc-erythropoietin (“Fc-EPO”) fusion proteins with improved pharmacokinetics. Nucleic acids, cells, and methods relating to the production and practice of the invention are also provided.
    Type: Grant
    Filed: December 30, 2004
    Date of Patent: December 16, 2008
    Assignee: Merck Patent GmbH
    Inventors: Stephen D. Gillies, Scott Lauder
  • IL-7 fusion proteins
    Patent number: 7323549
    Abstract: The invention is directed to a fusion protein which includes a first portion including an immunoglobulin (Ig) chain and a second portion including interleukin-7 (IL-7).
    Type: Grant
    Filed: December 30, 2004
    Date of Patent: January 29, 2008
    Assignee: EMD Lexigen Research Center Corp.
    Inventors: Scott Lauder, Stephen D. Gillies
  • Fc-erythropoietin fusion protein with improved pharmacokinetics
    Publication number: 20050192211
    Abstract: The present invention provides Fc-erythropoietin (“Fc-EPO”) fusion proteins with improved pharmacokinetics. Nucleic acids, cells, and methods relating to the production and practice of the invention are also provided.
    Type: Application
    Filed: December 30, 2004
    Publication date: September 1, 2005
    Applicant: EMD Lexigen Research Center Corp.
    Inventors: Stephen Gillies, Scott Lauder
  • IL-7 fusion proteins
    Publication number: 20050164352
    Abstract: The invention is directed to a fusion protein which includes a first portion including an immunoglobulin (Ig) chain and a second portion including interleukin-7 (IL-7).
    Type: Application
    Filed: December 30, 2004
    Publication date: July 28, 2005
    Applicant: EMD Lexigen Research Center Corp.
    Inventors: Scott Lauder, Stephen Gillies
  • Enhancing the circulating half-life of interleukin-2 proteins
    Publication number: 20050069521
    Abstract: Disclosed are compositions and methods for enhancing the circulating half-life of interleukin-2 proteins.
    Type: Application
    Filed: August 27, 2004
    Publication date: March 31, 2005
    Applicant: EMD Lexigen Research Center Corp.
    Inventors: Stephen Gillies, Scott Lauder, Jeffrey Way